News

Two presentations found that losing Good Days copay assistance forced retina patients onto bevacizumab, worsening anatomic outcomes and visual acuity despite more frequent dosing. Researchers said this highlights the importance of copay assistance in maintaining disease stability.

The anti-inflammatory effects of statins may explain the lower risk of proliferative vitreoretinopathy.

On a state-by-state basis, Nebraska had the highest rate and New Jersey, the lowest, according to data presented today.

Argentina's healthcare tradeoffs are playing out in real time. U.S. leaders should be paying attention.

Vabysmo reduced injection burden in both untreated and previously treated patients without impacting vision or retinal thickness in a two-year real-world analysis.

Racial gaps in cancer mortality narrowed sharply since the 1990s, led by declines in certain cancer types, but disparities remain.

A real-world analysis of nearly 2,700 eyes with diabetic macular edema found about 30% of Eylea HD patients reached 12-week or longer dosing intervals, reducing treatment burden over time.

Results of a real-world evidence study show 40% nonpersistence after a year and 80% by year 7.

Ocular Therapeutics plans to submit a new drug application for the sustained-released axitinib/hydrogel implant to treat patients with wet AMD in the fourth quarter of 2026 with the brand name Axpaxli.

Investigator Charles C. Wykoff, M.D., Ph.D., discusses the full results of the GLOW2 study, which found that Zenkuda (tarcocimab) resulted in improvement in diabetic retinopathy, including in patients who were taking GLP-1 agonists for their diabetes.

A study in Advanced Functional Materials found that mRNA vaccine nanoparticles can survive drying and rehydration in microneedle patch material, offering a potential path toward vaccines that no longer require cold chain storage.

Disruption in copay assistance may be one of the reasons.

Real-world results from the ongoing ELARA study found every-four-week Eylea HD produced meaningful BCVA gains with a safety profile consistent with prior aflibercept trials.

Enlicitide, a macrocyclic peptide that binds PCSK9 and blocks LDL receptor interaction, is the first oral PCSK9 inhibitor FDA-approved to lower LDL-C.

Experts agreed that staging and surveillance imaging should be used when there is a 15% risk of metastasis.

Specific brainstem inhibitory neurons help the brain filter out distractions by suppressing competing sensory signals, allowing mice (and presumably humans) to stay focused.

The FTC has settled its antitrust case against Caremark, requiring changes to drug pricing and rebate practices with up to $8.5 billion in potential consumer savings over the next 10 years.

A new review suggests molecular biomarkers could help gauge lung cancer recurrence risk and guide surveillance, but the evidence is still thin.

Most favored nation pricing may well deliver lower drug costs in the short term. But the real ledger, measured in research not pursued, diseases not prioritized, and markets left behind, will take years to fully calculate.

Judi Health has also launched two new services: Judi Care for medical benefit administration and Judi Cloud for those who want to license the Judi platform.

Two-thirds of patients had leftover pills, and some used opioids beyond guideline-recommended durations, an FDA-backed study found.

In this conversation, Johns Hopkins researchers describe a newly identified population of brainstem neurons that are crucial for selective attention in mice and may offer fresh insight into ADHD in humans.

University of Michigan researchers found that the experimental DT-109 reduced liver inflammation and MASH severity in nonhuman primates by targeting Clostridium perfringens and restoring gut barrier integrity.

A former radiation oncologist turned chief medical officer, Rex Hoffman, M.D., MBA, has spent the past several years expanding his leadership footprint across Providence Holy Cross Medical Center’s health system while authoring multiple books aimed at helping physicians navigate the transition into executive roles.

Transparency Rising is the new name for Transparency-Rx, a trade group of smaller PBMs challenging the "big 3."

Employers cite broker recommendations, cost-control effectiveness, and long-term costs as top factors shaping GLP-1 coverage decisions, according to a new survey from the International Foundation of Employee Benefit Plans.

Large language models are sure-footed at supplying answers, but what happens in medical contexts when that certainty can be a liability?

As a wave of blockbuster biologics face loss of exclusivity, some hope that there may be a “second phase” of biosimilar adoption.